tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

IKT Stock Latest News

Inhibikase Therapeutics reports Q2 EPS (66c), consensus (67c)
The FlyInhibikase Therapeutics reports Q2 EPS (66c), consensus (67c)
1M ago
IKT
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
PremiumPress Releases
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
1M ago
IKT
IKT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
IKT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
IKT
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
PremiumPress Releases
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
1M ago
IKT
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
PremiumThe Fly
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
3M ago
IKT
Inhibikase Therapeutics files to sell 4.76M shares of common stock for holders
PremiumThe FlyInhibikase Therapeutics files to sell 4.76M shares of common stock for holders
3M ago
IKT
Inhibikase Therapeutics completes enrollment of Phase 2 ‘201’ trial
Premium
The Fly
Inhibikase Therapeutics completes enrollment of Phase 2 ‘201’ trial
3M ago
IKT
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Premium
Press Releases
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
3M ago
IKT
Inhibikase Therapeutics announces expansion to its therapeutic pipeline
PremiumThe Fly
Inhibikase Therapeutics announces expansion to its therapeutic pipeline
4M ago
IKT
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
PremiumPress Releases
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
4M ago
IKT
Inhibikase Therapeutics price target lowered to $23 from $27 at H.C. Wainwright
PremiumThe Fly
Inhibikase Therapeutics price target lowered to $23 from $27 at H.C. Wainwright
4M ago
IKT
Inhibikase announces pricing of registered direct offering, warrant inducement
PremiumThe Fly
Inhibikase announces pricing of registered direct offering, warrant inducement
4M ago
IKT
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
PremiumPress ReleasesInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
4M ago
IKT
Inhibikase Therapeutics reports Q1 EPS (73c) vs. (98c) last year
Premium
The Fly
Inhibikase Therapeutics reports Q1 EPS (73c) vs. (98c) last year
4M ago
IKT
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Premium
Press Releases
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
4M ago
IKT
Inhibikase announces request for withdrawal of S-1 registration statement
PremiumThe Fly
Inhibikase announces request for withdrawal of S-1 registration statement
4M ago
IKT
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
PremiumPress Releases
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
4M ago
IKT
IKT Earnings this Week: How Will it Perform?
PremiumPre-Earnings
IKT Earnings this Week: How Will it Perform?
4M ago
IKT
Inhibikase Therapeutics announces final pre-IND meeting outcomes for IkT-001Pro
PremiumThe Fly
Inhibikase Therapeutics announces final pre-IND meeting outcomes for IkT-001Pro
4M ago
IKT
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
PremiumPress ReleasesInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
4M ago
IKT
Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials
Premium
Company Announcements
Inhibikase Therapeutics Faces Legal Dispute Amid Clinical Trials
5M ago
8K
IKT
Inhibikase Therapeutics files to sell common stock, warrants, no amount given
Premium
The Fly
Inhibikase Therapeutics files to sell common stock, warrants, no amount given
5M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >